Bicara Therapeutics (BCAX) Cash from Financing Activities (2023 - 2026)

Bicara Therapeutics has reported Cash from Financing Activities for 4 years, with the latest figure at $163.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 35409.78% year-over-year to $163.3 million; the trailing twelve-month figure through Mar 2026 stood at $195.1 million (down 41.63% YoY), and the FY2025 full-year result was $32.3 million, down 90.34% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $163.3 million, up from $31.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $334.1 million in Q3 2024, with the low at -$975000.0 in Q4 2024.
• Historically, Cash from Financing Activities has averaged $72.4 million across 4 years, with a median of $597000.0 in 2024.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities tumbled 100.5% — and 2026, when it surged 35409.78%.
• Bicara Therapeutics' Cash from Financing Activities stood at $194.7 million in 2023, then plunged by 100.5% to -$975000.0 in 2024, then jumped by 3303.08% to $31.2 million in 2025, then surged by 423.04% to $163.3 million in 2026.
• The last three Cash from Financing Activities figures came in at $163.3 million (Q1 2026), $31.2 million (Q4 2025), and $436000.0 (Q3 2025), per Business Quant data.